Department of Bioscience and Biotechnology, Banasthali University, Vanasthali, Rajasthan 304022, India.
Department of Physical Education and Sports Sciences, Acharya Nagarjuna University, Ongole 523001, Andhra Pradesh, India.
Curr Drug Metab. 2020;21(3):221-225. doi: 10.2174/1389200221666200310113118.
Breast cancer (BC) accounts for one of the most prevalent malignancies in the world. Inflammatory molecules modulate tumor microenvironment in BC that promotes tumor growth and metastasis. NF-κB (a transcription factor) that regulates multiple immune functions and acts as a crucial mediator of inflammatory responses.
The present study is aimed to quantitatively summarize the relation of NFKB1-94 ATTG (I, insertion/D, deletion) variant and risk of BC.
Further, the meta-analysis includes three independent case-control investigations that focus on NFKB1-94, ATTG I/D polymorphism, and BC patients. Web of Science, PubMed and Embase databases were used to retrieve relevant data. OR and 95% confidence interval of pooled studies were analyzed by using the MetaGenyo web tool.
This study revealed a high heterogeneity. In all three genetic comparison models, the NFKB1-94 ATTG I/D variant is not related to the risk of BC. Further, no publication bias on the connection between NFKB1-94 ATTG I/D variant and risk of BC was observed.
To summarize, our meta-analysis demonstrates that the NFKB1-94 ATTG I/D polymorphism is not a major risk factor for BC.
乳腺癌（BC）是世界上最常见的恶性肿瘤之一。炎症分子调节 BC 中的肿瘤微环境，促进肿瘤生长和转移。NF-κB（一种转录因子）调节多种免疫功能，是炎症反应的重要介质。
本研究旨在定量总结 NFKB1-94 ATTG（I，插入/D，缺失）变体与 BC 风险的关系。
此外，该荟萃分析包括三项针对 NFKB1-94、ATTT I/D 多态性和 BC 患者的独立病例对照研究。使用 Web of Science、PubMed 和 Embase 数据库检索相关数据。使用 MetaGenyo 网络工具分析汇总研究的 OR 和 95%置信区间。
本研究显示存在高度异质性。在所有三种遗传比较模型中，NFKB1-94 ATTG I/D 变体与 BC 风险无关。此外，未观察到 NFKB1-94 ATTG I/D 变体与 BC 风险之间存在发表偏倚。
总之，我们的荟萃分析表明，NFKB1-94 ATTG I/D 多态性不是 BC 的主要危险因素。
